{"id":"lmwh-parnaparin-subcutaneously","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated transaminases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Parnaparin works by potentiating antithrombin III-mediated inactivation of coagulation factors, particularly factor Xa (more than factor IIa), thereby preventing thrombin generation and fibrin clot formation. This anticoagulant effect is used to prevent and treat thromboembolism. The subcutaneous route provides predictable pharmacokinetics with a longer half-life compared to unfractionated heparin.","oneSentence":"Parnaparin is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:15.187Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prophylaxis and treatment"},{"name":"Deep vein thrombosis prevention and treatment"},{"name":"Pulmonary embolism prevention and treatment"}]},"trialDetails":[{"nctId":"NCT00362947","phase":"PHASE3","title":"Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2006-08","conditions":"Thrombophlebitis","enrollment":664}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LMWH parnaparin subcutaneously","genericName":"LMWH parnaparin subcutaneously","companyName":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","companyId":"irccs-azienda-ospedaliero-universitaria-di-bologna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Parnaparin is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboembolism prophylaxis and treatment, Deep vein thrombosis prevention and treatment, Pulmonary embolism prevention and treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}